亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Management of clinical infections of Escherichia coli by new β-lactam/ β-lactamase inhibitor combinations

舒巴坦钠 头孢吡肟 头孢哌酮 头孢他啶 微生物学 β-内酰胺酶抑制剂 阿维巴坦 氨苄西林 肉汤微量稀释 头孢菌素 生物 最小抑制浓度 抗生素 大肠杆菌 抗生素耐药性 铜绿假单胞菌 细菌 亚胺培南 生物化学 遗传学 基因
作者
Ashraf Ahmed Kadry,May A. El‐Antrawy,Amira M. El-Ganiny
出处
期刊:Iranian journal of microbiology [Tehran University of Medical Sciences]
卷期号:14 (4): 466-474 被引量:8
标识
DOI:10.18502/ijm.v14i4.10232
摘要

Background and Objectives: Escherichia coli (E. coli) is an important member of Enterobacteriaceae family involved in severe infections. The increased rate of resistance towards different classes of antibiotics limits their treatment options. The aim of this study was to assess the in vitro activity of classical and novel combinations of β-lactam/ β-lactamase inhibitor against E. coli clinical isolates. Materials and Methods: 140 clinical isolates of E. coli were collected from clinical specimens from Gastrointestinal Sur- gery Center (GISC) in Egypt. Extended spectrum β-lactamase (ESBL) was detected by double disk synergy test. Further- more, the minimum inhibitory concentrations (MICs) for five different combinations were determined using the broth mi- crodilution method including: amoxicillin/clavulanate and ampicillin/sulbactam as an example for classical combinations and cefoperazone/sulbactam, ceftazidime/avibactam, and cefepime/enmetazobactam as an example for new combinations. Results: The percentage of ESBL production among the tested isolates was 46.4%. Isolates were highly resistant to classical β-lactam/ β-lactamase inhibitor combinations, where (40.7%) and (42.9%) of isolates were resistant to amoxicillin/clavula- nate and ampicillin/sulbactam, respectively. While new β-lactam/ β-lactamase inhibitor combinations had promising inhib- itory action. The addition of novel β-lactamase inhibitors restored the susceptibility of isolates, where (94.3%) of isolates became susceptible to ceftazidime/avibactam combination, followed by cefoperazone/sulbactam (89.2%) and cefepime/en- metazobactam (85.7%). The synergistic effect seems to be effective where ceftazidime and avibactam were synergistic in 80% of isolates. Conclusion: The antibacterial activity of some antimicrobial agents can be enhanced by the addition of new β-lactamase inhibitors. Further in vivo investigation is needed to confirm their therapeutic efficacy against local isolates.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研通AI65的应助被阿腾采纳,获得10
4秒前
肖肖关注了科研通微信公众号
5秒前
6秒前
7秒前
开朗的千雁完成签到 ,获得积分10
8秒前
weako发布了新的文献求助10
9秒前
斯文败类的应助被开心的中心采纳,获得10
10秒前
369ninja发布了新的文献求助10
13秒前
辛勤元芹发布了新的文献求助10
13秒前
hgl完成签到,获得积分10
13秒前
stooyan的应助被王星晓采纳,获得100
14秒前
14秒前
wanci的应助被Clearday采纳,获得10
15秒前
15秒前
自由滑大王完成签到 ,获得积分10
19秒前
酷炫如曼完成签到,获得积分10
20秒前
烨无殇完成签到,获得积分10
20秒前
Anla完成签到,获得积分10
24秒前
26秒前
27秒前
agnway完成签到,获得积分10
29秒前
搞怪的老九的应助被涵泽采纳,获得10
29秒前
lidocaine完成签到 ,获得积分10
30秒前
para完成签到,获得积分10
32秒前
肖肖发布了新的文献求助10
32秒前
xi完成签到 ,获得积分10
32秒前
33秒前
山茶花开完成签到,获得积分10
33秒前
希望天下0贩的0的应助被Sissi采纳,获得10
33秒前
欢呼凝海完成签到 ,获得积分10
36秒前
科研通AI2S的应助被神勇的筝采纳,获得30
36秒前
zzjj完成签到 ,获得积分10
38秒前
41秒前
43秒前
44秒前
maki完成签到,获得积分10
47秒前
q2026完成签到 ,获得积分20
47秒前
123完成签到,获得积分10
48秒前
缓慢的秋荷完成签到,获得积分10
48秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778